Targeted Therapies in Development for Melanoma
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, highlights targeted therapies in development for melanoma.
Clinical Pearls
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, highlights targeted therapies in development for melanoma.
- Trials are planned looking at several targeted therapies and combinations of therapies, including CDK 4/6 inhibitors, BRAF or MEK inhibitors combined with MDM2 inhibitors, and BRAF plus MEK inhibitors combined with PD-1 antibodies
- Inhibition at the top of a pathway may not be the most efficacious strategy, as in the case of receptor tyrosine kinase inhibitors
- Long favors approaching treatment with the immune system or with inhibitors of AKT/PI3K, CDK 4/6, or HDAC
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
